CRMD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CRMD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cormedix's Free Cash Flow for the three months ended in Dec. 2024 was $-5.63 Mil. Cormedix's Revenue for the three months ended in Dec. 2024 was $31.21 Mil. Therefore, Cormedix's FCF Margin % for the quarter that ended in Dec. 2024 was -18.02%.
As of today, Cormedix's current FCF Yield % is -11.50%.
The historical rank and industry rank for Cormedix's FCF Margin % or its related term are showing as below:
During the past 13 years, the highest FCF Margin % of Cormedix was -116.70%. The lowest was -37809.23%. And the median was -8735.26%.
The historical data trend for Cormedix's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cormedix Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
FCF Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
-9,238.91 | -11,821.99 | -37,809.23 | - | -116.70 |
Cormedix Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
FCF Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | -1,746.28 | -119.24 | -18.02 |
For the Biotechnology subindustry, Cormedix's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Cormedix's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Cormedix's FCF Margin % falls into.
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
Cormedix's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as
FCF Margin | = | Free Cash Flow (A: Dec. 2024 ) | / | Revenue (A: Dec. 2024 ) |
= | -50.731 | / | 43.472 | |
= | -116.70 % |
Cormedix's FCF Margin for the quarter that ended in Dec. 2024 is calculated as
FCF Margin | = | Free Cash Flow (Q: Dec. 2024 ) | / | Revenue (Q: Dec. 2024 ) |
= | -5.625 | / | 31.21 | |
= | -18.02 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Cormedix's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Elizabeth Masson | officer: EVP, Head of Clinical Ops. | 400 CONNELL DRIVE, SUITE 5000, BERKELEY HEIGHTS NJ 07922 |
Erin Mistry | officer: Chief Commercial Officer | 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922 |
Joseph Todisco | director, officer: Chief Executive Officer | 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807 |
Alan W Dunton | director | VICURON PHARMACEUTICALS INC, 455 S GULPH ROAD SUITE 305, KING OF PRUSSIA PA 19406 |
Myron Kaplan | director | C/O KLEINBERG, KAPLAN, WOLFF & COHEN, PC, 551 FIFTH AVENUE, 18TH FLOOR, NEW YORK NY 10176 |
Paulo F Costa | director | MACROGENICS, INC., ONE CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
Robert A Stewart | director | 360 MT. KEMBLE AVENUE, MORRISTOWN NJ 07960 |
Janet Dillione | director | ONE WAYSIDE ROAD, BURLINGTON MA 01803 |
Matthew T David | officer: EVP, Chief Financial Officer | 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922 |
Thomas Nusbickel | officer: EVP, Chief Commercial Officer | 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS NJ 07922 |
Gregory Scott Duncan | director | 44 MILTON AVENUE, ALPHARETTA GA 30009 |
Steven W Lefkowitz | director | SIX HARRISON STREET, NEW YORK NY 10013 |
Mehmood Khan | director | 700 ANDERSON HILL ROAD, PURCHASE NY 10577 |
Armstrong Jr. John L. | officer: Exec VP of Tech Operations | C/O CORMEDIX INC., 1430 U.S. HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921 |
Phoebe Mounts | officer: General Counsel | 400 CONNELL DRIVE, SUITE 5000, BERKELEY HEIGHTS NJ 07822 |
From GuruFocus
By Marketwired • 09-09-2024
By Marketwired • 01-07-2025
By Marketwired • 10-30-2024
By Marketwired • 10-24-2024
By Marketwired • 05-10-2024
By Marketwired • 05-09-2024
By Marketwired • 09-19-2024
By Marketwired • 01-21-2025
By Marketwired • 06-18-2024
By Marketwired • 09-13-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.